Federal Register / Vol. 72, No.
118 / Wednesday, June 20, 2007 / Notices 34027
Contact Person: Jay Joshi, PhD, Scientific
Review Administrator, Center for Scientific
Review, National Institutes of Health, 6701
Rockledge Drive, Room 5184, MSC 7846,
Bethesda, MD 20892, (301) 435–1184,
joshij@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Brain
Disorders and Clinical Neuroscience-
Members.
Date: July 19, 2007.
Time: 2 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Jay Joshi, PhD, Scientific
Review Administrator, Center for Scientific
Review, National Institutes of Health, 6701
Rockledge Drive, Room 5184, MSC 7846,
Bethesda, MD 20892, (301) 435–1184,
joshij@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Xenopus
Genetics and Genomics.
Date: July 23–24, 2007.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Barbara J. Thomas, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2218,
MSC 7890, (301) 435–0603,
bthomas@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Small
Business: Arthritis, Connective Tissue and
Skin Sciences.
Date: July 23, 2007.
Time: 8 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Watergate Hotel, 2650 Virginia
Avenue, NW., Washington, DC 20037.
Contact Person: Harold M. Davidson, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4222,
MSC 7814, Bethesda, MD 20892, (301) 435–
1776, davidsoh@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Stem Cells,
Neuron Migration and Guidance.
Date: July 23, 2007.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Carol Hamelink, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5040H,
rwilkins on PROD1PC63 with NOTICES
MSC 7850, Bethesda, MD 20892, (301) 451–
1328, hamelinc@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Small
Business: Digestive Sciences and
Bioengineering.
VerDate Aug<31>2005 18:25 Jun 19, 2007 Jkt 211001
Date: July 23, 2007.
Time: 1 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Bonnie L. Burgess-Beusse,
PhD, Scientific Review Administrator, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2191C,
MSC 7818, Bethesda, MD 20892, (301) 435–
1783, beusseb@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.847–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 12, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–3014 Filed 6–19–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Anti-Mesothelin Antibodies
Useful for Immunological Assays
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in U.S. Patent Application
No. 60/681,104, filed May 12, 2005,
entitled ‘‘Anti-Mesothelin Antibodies
Useful For Immunological Assays’’ [E–
015–2005/0–US–01] and PCT
Application No. PCT/US2006/018502,
filed May 11, 2006, entitled ‘‘Anti-
Mesothelin Antibodies Useful For
Immunological Assays’’ [E–015–2005/0–
PCT–02] to Cambridge Antibody
Technology, Ltd., which has offices in
Cambridge, United Kingdom. The patent
rights in these inventions have been
assigned to the United States of
America.
The prospective exclusive license
territory may be worldwide, and the
field of use may be limited to the use
of the SSIP immunoconjugate and
variants thereof for the treatment of
mesothelin expressing cancers.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 E:\FR\FM\20JNN1.SGM
Technology Transfer on or before
August 20, 2007 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive license should
be directed to: Jesse S. Kindra, J.D.,
M.S., Technology Licensing Specialist,
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
5559; Facsimile: (301) 402–0220; E-mail:
kindraj@mail.nih.gov.
SUPPLEMENTARY INFORMATION: This
technology relates to anti-mesothelin
antibodies with a particularly high
affinity for mesothelin and the ability to
be used in immunological assays for
detecting the presence of mesothelin in
biological samples. The anti-mesothelin
antibodies are well-suited for the
diagnosis and treatment of cancers of
the ovary, stomach, squamous cells,
mesotheliomas and other malignant
cells expressing mesothelin.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR Part 404.7. The
prospective exclusive license may be
granted unless within sixty (60) days
from the date of this published notice,
the NIH receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: June 11, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer,Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–11828 Filed 6–19–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
The Critical Infrastructure Partnership
Advisory Council (CIPAC)
AGENCY: Directorate for National
Protection and Programs, DHS.
ACTION: Committee management; update
on CIPAC committee membership.
20JNN1